Roblan / Shutterstock.com
Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board (PTAB) review the validity of a patent owned by Alpex Pharma.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kyle Bass; USPTO; IPR; PTAB; Alpex Pharma; Suprenza; Erich Spangenberg